© 2010 BioSystems International
Kapcsolat:
Debrecen, Nagyerdei krt. 98.
Projekt támogató:
Design & Code
The plasma proteome profiling with monoclonal antibody based protein chips is a promising new tool in biomarker discovery that can be used to identify novel plasma markers in a wide variety of diseases. Recently a novel system – QuantiPlasm69 (QP69) – has been introduced by Randox Laboratories using 69 monoclonal antibodies (mAbs) – developed by BioSystems International – that can recognize different human plasma proteins. The mAbs are immobilized on 9x9 mm ceramic chips and a biotinylated plasma protein tracer is competing with plasma proteins in the tested sample for mAb binding. The amount of the bound tracer is determined by a streptavidin-peroxidase conjugate and a chemiluminescence substrate. We aimed to evaluate the analytical properties of QP69.
tovább»Biosystems International and Microbiochips sign collaboration agreement to commer- cialize PlasmaScan™ antibody microarray products.
Biosystems International (BSI) a biotech- nology company focused on the development of novel monoclonal antibody-based diagnostics for cancer and metabolic diseases has established a licensing agreement with the Lohocla Research Corporation for the use of BSI’s patented monoclonal antibody proteo- mics platform for the discovery of novel alcoholism liver disease biomarkers in blood.
Biosystems International (BSI) a biotech- nology company focused on the development of novel monoclonal antibody-based diagnostics for cancer and metabolic diseases has established a licensing agreement with the Lohocla Research Corporation for the use of BSI’s patented monoclonal antibody proteo- mics platform for the discovery of novel alcoholism liver disease biomarkers in blood.
Biosystems International and Microbiochips sign collaboration agreement to commer- cialize PlasmaScan™ antibody microarray products.
© 2010 BioSystems International
Kapcsolat:
Debrecen, Nagyerdei krt. 98.
Projekt támogató:
Design & Code